Sodium Fluorescein as an Optical Label to Evaluate Subretinal Injection

Simunovic, Matthew P.; Osaadon, Perach; Too, Lay Khoon

doi:10.1097/iae.0000000000002800

Cited by 5 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its staining mechanism includes cell surface aggregation, cellular absorption, and invasion around cells, providing reliable objective evidence for the diagnosis of corneal diseases [22] . In the case of corneal epithelial injury, uorescein sodium typically diffuses into the cells and accumulates at the site of injury, presenting as a bright green color [23] .…”

Section: Resultsmentioning

confidence: 99%

New Insight in Pain Relief and Reparative Efficacy of rh-EGF on Rabbit Corneal Injury Running title：Rh-EGF: Pain Relief and Repair in Corneal Injury

Gao,

Song,

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose This study aimed to investigate recombinant human epidermal growth factor (rh EGF) in corneal wound healing while also providing the effects of pain relief. Methods Twenty experimental rabbits were randomly divided into four groups, five rabbits each. All rabbits were exposed to a 5 kW AC for 5 minutes. Each rabbit was only irradiated on one side, and their natural blinking was observed during this process. After modeling, each group was separately subjected to treatments with physiological saline, oxybuprocaine hydrochloride, rh EGF, and a combination of medications. Results Compared to the control group, the experimental group receiving recombinant human epidermal growth factor (rh EGF) treatment exhibited a significant decrease in blink frequency and wiping frequency (P < 0.05), with notably superior effects compared to the group treated with oxibuprocaine hydrochloride. Furthermore, compared to the oxibuprocaine hydrochloride group, the experimental group receiving rh EGF treatment showed a significant reduction in conjunctival congestion and prolonged secretion duration (P < 0.05), along with a shorter corneal epithelial recovery time compared to the oxibuprocaine hydrochloride group (P < 0.05). Fluorescein sodium staining revealed a smaller stained area in the experimental group receiving rh EGF treatment. Additionally, inflammatory factors IL-1β, IL-6, and TNF-α were markedly decreased in the rh EGF treatment group, while the anti-inflammatory factor IL-10 exhibited a significant increase. Conclusions We confirmed that rh EGF not only promotes corneal repair but also possesses certain analgesic effects, which providing new perspectives and strategies for future research in the field of corneal injury treatment and repair.

show abstract

Section: Resultsmentioning

confidence: 99%

New Insight in Pain Relief and Reparative Efficacy of rh-EGF on Rabbit Corneal Injury Running title：Rh-EGF: Pain Relief and Repair in Corneal Injury

Gao,

Song,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Intraocular fluid will undergo fluorophotometric analysis using a previously published protocol validated in our laboratory, which negates the effects of possible extinction of fluorescence from contamination with blood. 1 Repeat calibration and cross-referencing with undiluted therapeutic solution will be performed for each sample to avoid variation introduced through variations in the concentration of fluorescein (introduced in the manufacture of fluorescein or the dilution procedure). Duration of surgery will be evaluated from surgical videos and/or case documentation in the patient's surgical file.…”

Section: Discussionmentioning

confidence: 99%

“…First, we aim to employ a quantitative method developed in our laboratory which uses sodium fluorescein as an optical label to measure the reflux of subretinally delivered drugs which we have described in detail previously. 1 Second, we aim to compare 1-step and 2-step injection techniques in terms of percentage of therapeutic solution 'wasted' (as measured in the first aim) during the surgical procedure to deliver therapeutic solutions into the subretinal space.…”

Section: Aimsmentioning

confidence: 99%

See 1 more Smart Citation

Two-step versus 1-step subretinal injection to compare subretinal drug delivery: a randomised study protocol

et al. 2021

Self Cite

View full text Add to dashboard Cite

IntroductionThere is increasing interest in subretinal injections as a surgical procedure, largely as a result of emerging treatments for ocular diseases which necessitate this manoeuvre. However, surgical variables in the efficacy of such treatments have to date been largely overlooked and the proportion of drug which reaches the intended compartment of the subretinal space remains unknown. Our aims are twofold: first, to determine the proportion of subretinally injected medication retained following surgical delivery and second, to compare two different techniques of injection (‘1-step’ vs ‘2-step’).MethodsWe outline a randomised controlled trial of subretinal injection of alteplase following vitrectomy for the management of submacular haemorrhage secondary to age-related macular degeneration. Patients will be randomised to receive either 1-step injection, where the therapeutic solution simultaneously defines the surgical plane or 2-step injection, where the surgical plane is first identified with balanced salt solution prior to injection of subretinal alteplase, as outlined below. Sodium fluorescein will be used as an optical label to track drug reflux into the vitreous cavity using quantitative protocols established in our laboratory. All patients will undergo fluid air exchange at the completion of surgery, with injection of bevacizumab 1.25 mg and 20% sulfahexafluoride gas as the vitreous substitute (both of which may help improve outcomes). Alteplase, sodium fluorescein and bevacizumab will all be used for off-label indications in the trial.Ethics and disseminationEthical approval has been obtained from the South Eastern Sydney Local Health District’s Human Research Ethics Committee (HREC 17/092). The results of this trial will be disseminated in peer-reviewed proceedings (associated with conference presentation) and in scholarly journals.Trial registration numberACTRN12619001121156.

show abstract